Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses, sources had said.
The phase 2 human clinical trial of the Oxford Covid-19 vaccine candidate in the country by Pune-based Serum Institute of India (SII) started today.
The observer-blind, randomised controlled study to determine the safety and immunogenicity of ``Covishield`` on healthy Indian adults will begin at Bharati Vidyapeeth Medical College and Hospital in Pune.
Serum Institute of India has partnered with British-Swedish pharma company AstraZeneca for manufacturing the Covid-19 vaccine candidate, developed by the University of Oxford.
Initial results of the first two-phases of trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses, sources had said.
Your support to NYOOOZ will help us to continue create and publish news for and from smaller cities, which also need equal voice as much as citizens living in bigger cities have through mainstream media organizations.
.png)
